Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$12.65 USD
-0.71 (-5.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.39 -0.26 (-2.06%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Income Statements
Fiscal Year end for Assembly Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 7 | 0 | 6 | 79 | 16 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 7 | 0 | 6 | 79 | 16 |
Selling & Adminstrative & Depr. & Amort Expenses | 72 | 94 | 139 | 144 | 119 |
Income After Depreciation & Amortization | -65 | -94 | -133 | -65 | -103 |
Non-Operating Income | 3 | 1 | 0 | 3 | 4 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -61 | -93 | -132 | -62 | -98 |
Income Taxes | 0 | 0 | -3 | 0 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -61 | -93 | -130 | -62 | -98 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -61 | -93 | -130 | -62 | -98 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -66 | -93 | -90 | -64 | -104 |
Depreciation & Amortization (Cash Flow) | -1 | 1 | 43 | 1 | -1 |
Income After Depreciation & Amortization | -65 | -94 | -133 | -65 | -103 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.58 | 4.03 | 3.61 | 2.95 | 2.19 |
Diluted EPS Before Non-Recurring Items | -13.38 | -23.05 | -24.49 | -21.01 | -44.66 |
Diluted Net EPS (GAAP) | -13.38 | -23.05 | -36.01 | -21.01 | -44.66 |
Fiscal Year end for Assembly Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 7.16 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 7.16 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.72 | 15.04 | 17.49 | 19.56 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -12.56 | -15.04 | -17.49 | -19.56 |
Non-Operating Income | NA | 1.62 | 0.63 | 0.59 | 0.61 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -10.93 | -14.42 | -16.90 | -18.95 |
Income Taxes | NA | 0.03 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.96 | -14.42 | -16.90 | -18.95 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.96 | -14.42 | -16.90 | -18.95 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | NA | 4.38 | 4.35 | 4.25 |
Diluted EPS Before Non-Recurring Items | NA | NA | -3.24 | -3.84 | -4.44 |
Diluted Net EPS (GAAP) | NA | -1.86 | -3.24 | -3.84 | -4.44 |